Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2022-000302-10-CZ
EUCTR2022-000302-10-CZ
Active, not recruiting
Phase 1

Significance of T cell response to vaccination against SARS-CoV2 for leukemic patients with weakend immune system - UHKT-COVID19

Institute of hematology and blood transfusion0 sites30 target enrollmentJanuary 25, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsRecipients of cell therapy (allo HSCT, CAR19 T cells) indicated to vaccination against COVID19Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
DrugsComirnaty concentrate for dispersion for injectionSpikevax COVID-19 Vaccine Moderna dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified)

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Recipients of cell therapy (allo HSCT, CAR19 T cells) indicated to vaccination against COVID19
Sponsor
Institute of hematology and blood transfusion
Enrollment
30
Status
Active, not recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 25, 2022
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Institute of hematology and blood transfusion

Eligibility Criteria

Inclusion Criteria

  • •Adult recipients of cell therapy (allo\-HSCT, CAR19 T cells) indicated to vaccination against COVID19\. 30 patients, 20 healthy volunteers vaccinated against COVID19\.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 15
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range 15

Exclusion Criteria

  • •Uncompleted vaccination schedule.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Study of immune responses after vaccination with an influenza vaccine (Inflexal V) in patients who have undergone hematopoietic allogeneic stem cell transplantation.Allogeneic stem cell transplantationTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2013-003403-19-SEKarolinska University Hospital30
Not yet recruiting
Not Applicable
Safety and efficacy of vaccination with T cell-dependent and T cell-independent primary and recall antigens in patients with rheumatoid arthritis treated with anti TNF-* antibodies (adalimumab) or anti B cell therapy (Rituximab).Rheumatoid arthritis RA Vaccination100038161000225210023213
NL-OMON30739Academisch Medisch Centrum40
Not yet recruiting
Not Applicable
Post vaccination immunological response and immune monitoring for SARS-CoV-2
CTRI/2021/08/035338Medanta Institute of Education and Research
Unknown
Not Applicable
Immunogenicity of Influenza Vaccine in Long Term CareInfluenza
NCT02933723Insight Therapeutics, LLC200
Recruiting
Phase 3
Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University.Assessing the immunological responses and adverse reactions elicited by the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccinationCOVID-19SAR-CoV-2 second booster doseheterologous vaccinationBNT162b2CoronaVachealthcare workers
TCTR20221112001The National Science Research and Innovation Fund340